

# Let's stop HIV

Nuove prospettive  
e popolazioni speciali

*Chairs: C. Mussini, L. Sighinolfi*



Con il patrocinio di



Hotel Savoia *Rimini* 2-3 aprile 2019

*Programma Scientifico*

# MEET TEST TREAT

CAMPAGNA SULLA RIDUZIONE DEL DANNO

## People Who Use Drugs' Continuum of care in the context of HCV infection: Real Life data.

E. Teti<sup>1,2</sup>, L. Foroghi<sup>1</sup>, V. Malagnino<sup>1</sup>, E. Rossi<sup>2</sup>, G. Rodoquino<sup>2</sup>, D. Masci<sup>2</sup>,  
P. Sammarco<sup>2</sup>, L. Sarmati<sup>1</sup>, M. Andreoni<sup>1</sup>, M. Barra<sup>2</sup>

<sup>1</sup> UOC Malattie Infettive, Policlinico Tor Vergata, Roma, Italia

<sup>2</sup> Fondazione Villa Maraini, Roma, Italia



# HIV/HCV Continuum of Care




HepC: Cure  
HIV: U=U

**Undetectable = Untransmittable**

PREVENTION


# Meet, Test and Treat: 4 passaggi che fanno la differenza



# HCV Seroprevalence among PWID


Results (1)

PWUD (n. 673)



Ab HCV+ Ab HCV-

PWID (n. 326)



PWID (326/673 – 48.4%) PWUD No PWID

Periodo: giugno 2015 – giugno 2018



HIV prevalence: 2.5%

	Univariate OR	95% C.I.	P-value	Multivariate OR	95% C.I.	P-value
Age >35, years	3,03	2,17-4,25	<0,0001	3,00	1,78-5,80	<0,0001
Working	0,35	0,25-0,50	<0,0001	0,36	0,22-0,61	<0,0001
Previous HCV-test	7,91	5,0-12,66	<0,0001	3,44	1,78-6,64	<0,0001
Heroin	4,65	3,09-7,01	<0,0001	0,78	0,37-1,64	0,51
Multidrug users	1,07	0,77-1,49	0,66	-	-	-
Intravenous	26,86	15,9-43,3	<0,0001	16,24	7,97-33	<0,0001
Syringe exchange in last year	0,97	0,68-1,39	0,90	-	-	-
Sex with IDU's	3,77	2,54-5,58	<0,0001	2,69	1,61-4,48	<0,0001



Unadjusted Potential Predictors of HCV positive test among the study population, Univariate logistic analysis. To test the predictive role of single variables for seroprevalence, univariate logistic regression was performed: only variables with a *P* value lower than .2 have been tested in the multivariate analysis. *P* values lower than .05 have been considered statistically significant.

Treatment adherence according to the four PWUD subgroups



Periodo: giugno 2015 – dicembre 2017  
 PWUD: n. 106

**«Lost to Follow up» Patients Have Equivalent Sustained Viral Response rates to Patients attending their Scheduled SVR12 Visit.»**  
 Boyle A; Oral Presentation,  
 INHSU, Lisbon 19-21 September 2018



## Epatite C: Iter diagnostico-terapeutico – 2018 Tossicodipendenti per via endovenosa



Tossicodipendenti per via endovenosa

132/722  
consumatori di sostanze



Test rapido positivo

53/132  
40.15%



Linkage To Care con successo

47/53  
88.7%




Conferma di Epatite C Attiva

41/47  
87.2%



Inizio terapia

23/41  
56.1%



Guarigione (SVR12)

16/17



Terapia in corso


7/23

Cascata di Cura

94.1%  
di successo

(1 relapser per interruzione di terapia)

# HCV-PWID: “Change your mind, go where they are”



Find The **Missing** Millions.